BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22786730)

  • 1. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
    Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
    Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
    Kyle RA; Remstein ED; Therneau TM; Dispenzieri A; Kurtin PJ; Hodnefield JM; Larson DR; Plevak MF; Jelinek DF; Fonseca R; Melton LJ; Rajkumar SV
    N Engl J Med; 2007 Jun; 356(25):2582-90. PubMed ID: 17582068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
    Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A
    Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
    Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF
    Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation.
    Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Therneau TM; Kyle RA; Greipp PR; Gertz MA
    Am J Hematol; 2001 Dec; 68(4):269-75. PubMed ID: 11754416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
    Sezer O; Heider U; Zavrski I; Possinger K
    Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
    Pasqualetti P; Colantonio D; Casale R
    Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
    Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
    Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
    Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
    Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
    Kumar S; Rajkumar SV; Greipp PR; Witzig TE
    Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.
    Nasr SH; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Lacy M; Dispenzieri A; Rajkumar SV; Kyle RA; Leung N
    Am J Kidney Dis; 2012 Jun; 59(6):786-94. PubMed ID: 22417785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
    Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
    Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.
    Hillengass J; Fechtner K; Weber MA; Bäuerle T; Ayyaz S; Heiss C; Hielscher T; Moehler TM; Egerer G; Neben K; Ho AD; Kauczor HU; Delorme S; Goldschmidt H
    J Clin Oncol; 2010 Mar; 28(9):1606-10. PubMed ID: 20177023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoldering multiple myeloma.
    Gao M; Yang G; Kong Y; Wu X; Shi J
    Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma.
    Rossi D; Fangazio M; De Paoli L; Puma A; Riccomagno P; Pinto V; Zigrossi P; Ramponi A; Monga G; Gaidano G
    Cancer; 2010 May; 116(9):2188-200. PubMed ID: 20198709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
    Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.